Kyntra Bio
KYNB
208 hedge funds and large institutions have $2.84B invested in Kyntra Bio in 2020 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 66 increasing their positions, 72 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
68% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 22
7% more funds holding
Funds holding: 194 → 208 (+14)
4% more capital invested
Capital invested by funds: $2.73B → $2.84B (+$109M)
0.03% more ownership
Funds ownership: 3.02% → 3.05% (+0.03%)
8% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 72
38% less call options, than puts
Call options by funds: $18.8M | Put options by funds: $30.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$69M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$16.5M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$14.3M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$10M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$24M |
| 2 |
BlackRock
New York
|
-$17.9M |
| 3 |
Renaissance Technologies
New York
|
-$14.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$13.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.5M |
KYNB Hedge Fund Activity: Q3 2020 in Review
208 of the 4,969 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2020, worth a combined $2.84B — up 4% from $2.73B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KYNB positions and 22 closed out — a net gain of 15 holders — while 66 added to existing stakes and 72 trimmed.
The largest buyer was Primecap Management, adding an estimated $69M. The largest seller was Credit Suisse, cutting an estimated $24M.
- 208 institutional investors held Kyntra Bio (KYNB) as of Q3 2020, up from 194 in Q2 2020.
- Funds reported $2.84B of Kyntra Bio stock for Q3 2020, up 4% quarter-over-quarter.
- 37 funds opened new Kyntra Bio positions in Q3 2020 and 22 closed out, a net change of +15 holders.
- The largest Kyntra Bio buyer in Q3 2020 was Primecap Management, an estimated $69M added.
- The largest Kyntra Bio seller in Q3 2020 was Credit Suisse, an estimated $24M sold.
Based on aggregated 13F filings for Q3 2020.